Feb 19 (Reuters) - German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging ...

BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by ...

BioNTech has filed a lawsuit against Moderna in a Delaware federal court over allegations of patent infringement related to ...

BioNTech has filed a lawsuit against Moderna in a Delaware federal court, claiming infringement on a patent related to their COVID-19 vaccine technology. Moderna's vaccine, mNEXSPIKE, allegedly ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

This new filing is not an isolated event but represents another front in a protracted legal war between the two biotech firms. The conflict has a precedent: Moderna originally sued both BioNTech and ...

Shares in Moderna and BioNTech have imploded since their 2021 peaks, shaving billions of dollars from their founders’ fortunes. Growing anti-vax hysteria and RFK Jr.’s FDA will likely make the ...

The upcoming conference call is expected to feature substantial updates on BioNTech's clinical development programs. According to a recent strategic review, the company aims to have a total of 15 ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

FRANKFURT (Reuters) - Moderna and Pfizer-BioNTech are in a tight race to launch their COVID-19 vaccines in Europe after both applied for emergency EU approval on Tuesday, though there was uncertainty ...